Evidence map›Paper›PMID 23071394›Full record

ArticleInternational journal of nanomedicine2012

Development of a nanoporous and multilayer drug-delivery platform for medical implants.

Varvara Karagkiozaki, Eleftherios Vavoulidis, Panagiotis G Karagiannidis, Maria Gioti, Dimitrios G Fatouros, Ioannis S Vizirianakis, Stergios Logothetidis

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Membrane-BasedAnalytical chemistry · 2021
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Vascular distribution of nanomaterials.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Varvara KaragkiozakiLab for Thin Films-Nanosystems and Nanometrology, Physics Department, Aristotle University of Thessaloniki, Greece.
Eleftherios Vavoulidis
Panagiotis G Karagiannidis
Maria Gioti
Dimitrios G Fatouros
Ioannis S Vizirianakis
Stergios Logothetidis
Nanosystem (Russia) · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biodegradable polymers can be applied to a variety of implants for controlled and local drug delivery. The aim of this study is to develop a biodegradable and nanoporous polymeric platform for a wide spectrum of drug-eluting implants with special focus on stent-coating applications. It was synthesized by poly(DL-lactide-co-glycolide) (PLGA 65:35, PLGA 75:25) and polycaprolactone (PCL) in a multilayer configuration by means of a spin-coating technique. The antiplatelet drug dipyridamole was loaded into the surface nanopores of the platform. Surface characterization was made by atomic force microscopy (AFM) and spectroscopic ellipsometry (SE). Platelet adhesion and drug-release kinetic studies were then carried out. The study revealed that the multilayer films are highly nanoporous, whereas the single layers of PLGA are atomically smooth and spherulites are formed in PCL. Their nanoporosity (pore diameter, depth, density, surface roughness) can be tailored by tuning the growth parameters (eg, spinning speed, polymer concentration), essential for drug-delivery performance. The origin of pore formation may be attributed to the phase separation of polymer blends via the spinodal decomposition mechanism. SE studies revealed the structural characteristics, film thickness, and optical properties even of the single layers in the triple-layer construct, providing substantial information for drug loading and complement AFM findings. Platelet adhesion studies showed that the dipyridamole-loaded coatings inhibit platelet aggregation that is a prerequisite for clotting. Finally, the films exhibited sustained release profiles of dipyridamole over 70 days. These results indicate that the current multilayer phase therapeutic approach constitutes an effective drug-delivery platform for drug-eluting implants and especially for cardiovascular stent applications.

Indexed as

Drug-Eluting StentsBiocompatible MaterialsBlood PlateletsCells, CulturedCrystallizationDipyridamoleHumansLactic AcidNanocapsulesParticle SizePlatelet AdhesivenessPlatelet Aggregation InhibitorsPolyestersPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerPorosityBiocompatible MaterialsDipyridamoleLactic AcidNanocapsulesPlatelet Aggregation InhibitorspolycaprolactonePolyestersPolyglycolic AcidPolylactic Acid-Polyglycolic Acid Copolymeratomic force microscopydrug deliveryimplantspolymersspin-coatingstents

Identifiers

PMID23071394
PMCPMC3469098
OpenAlexW2083510128

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.